Select-d experience study

Cancer patients have a greater risk of venous thromboembolism than the general population. It is the commonest cause of death during chemotherapy. In this study, we explored patients and carers experience of cancer-associated thrombosis and its treatment.

About the project

Funder: Bayer
Time frame: 2016 - 2017: Completed
Publication: Palliative Medicine
Contact for more details:
 Professor Miriam Johnson and Dr Ann Hutchinson

The purposes of this project was to explore patient and carer experience of cancer-associated thrombodid (CAT) and of taking medication in the form of low-molecular weight heparin (LMWH) or a direct oral anticoagulant (DOAC) daily as part of the ‘select-d trial’.

37 patients and 9 carers were interviewed. Some were shocked and worried by the venous thromboembolism (VTE), whereas others felt it was relatively insignificant in the context of cancer. Most were unaware that VTE was a cancer-related risk. 

In general, patients found tablets to be more convenient, but patients found long-term LMWH acceptable, despite the side-effect profile, in the context of their cancer and its treatment.

Cancer patients should be informed of this risk and of VTE-related symptoms to encourage prompt help-seeking in this event and we are working with charities such as Thrombosis UK to make this happen.

For more on this research listen to a podcast with the authors discussing the findings and their recommendations and read our blog.